BIOQUAL, Inc., announced today that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

(Image Credits: Pixabay) Amid the growing burden of non-communicable diseases and ageing population, the pharmaceutical sector has thrived tremendously over the recent years. Industry leaders ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma skyrocketed by 281%. In 2024, Fierce Biotech reported 192 ...

Novo Nordisk, for its part, is expected to jump from 10th place to sixth this year, according to Evaluate Pharma’s consensus forecasts. Nevertheless, it’s Roche that’s been tipped to stand ...

Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker. Merck's cancer drug Keytruda ...

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...

“It seems like Mesoblast is finally getting there,” Wilkie said. Radiopharmaceuticals has emerged as one of hottest themes in the sector this year with Clarity Pharmaceuticals (ASX:CU6) a major ...